Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 4/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.42 |
| ▸ | KLK1 | P06870 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PLAU | P00749 | 2/20 | 0.40 |
| ▸ | PLAT | P00750 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KLK8 | O60259 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | KLK4 | Q9Y5K2 | 1/20 | 0.40 |
| ▸ | KYNU | Q16719 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21189145 | 0.85 | CASP1 (0.46) | CASP1ELANEPRTN3KLK1TP53 | |
| SCHEMBL21189146 | 0.85 | KYNU (0.46) | CASP1ELANEPRTN3KLK1TP53 | |
| SCHEMBL21189177 | 0.85 | KYNU (0.46) | CASP1ELANEPRTN3KLK1TP53 | |
| SCHEMBL57869 | 0.85 | KYNU (0.46) | CASP1ELANEPRTN3KLK1TP53 | |
| SCHEMBL57867 | 0.79 | CASP1 (0.47) | CASP1ELANEALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL21189142 | 0.77 | TACR1 (0.49) | CASP1ELANEKYNUTACR1 | |
| SCHEMBL56888 | 0.76 | CASP1 (0.47) | CASP1ELANEPRTN3KLK1KYNU | |
| SCHEMBL56936 | 0.76 | CASP1 (0.48) | CASP1ELANEPRTN3KLK1TP53 | |
| SCHEMBL56934 | 0.75 | CASP1 (0.53) | CASP1ELANEALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL21174049 | 0.74 | TACR1 (0.53) | CASP1ELANEALDH1A1KYNUTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774098-B2 | Nahlsgen optical resolution method | KYOTO UNIVERSITY (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20190225634-A1 | NAHLSGEN OPTICAL RESOLUTION METHOD | KYOTO UNIVERSITY (JP) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774098-B2 | Nahlsgen optical resolution method | HACL2, HAO2, HPD | CASP1 1294/4885ELANE 3823/4885PRTN3 3349/4885 |
| US-20190225634-A1 | NAHLSGEN OPTICAL RESOLUTION METHOD | HACL2, HAO2, HPD | CASP1 1294/4885ELANE 3823/4885PRTN3 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.